Home > Back to Publisher > Report Information

Conference Documentation: Pain Therapeutics (2010)

SMI Publishing, Ltd
June 7, 2010
SKU: SMI2771807

Abstract Table of Contents Related Reports

SMi ran its first conference on pain therapeutics in 2001, and has run a highly successful conference on this topic every year since. In 2010, our industry-leading Pain Therapeutics conference returns for its tenth year, and will build on the knowledge-base and reputation that SMi has in this area to deliver the most interesting and informative conference yet.

Taking place in London, UK, this conference will look at a wide range of issues withing the pain therapeutics arena. It will combine a study of the latest successes in the research and development phase with presentations covering the key themes of biomarkers and the cannabinoid approach.

Questions examined during the conference will include: Do cannabinoid medicines have a place in our pain arsenal? How do regulatory authorities treat emerging clinical development biomarkers. What are the latest targets being researched? How do we treat associated conditions for chronic pain? How effective is translational research for pain measurement? Attend this event to discover the latest success stories in researching and marketing pain therapeutics.

DAY 1
8.30 Registration and coffee
9.00 Chairman's opening remarks: Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford.
9.10 Regulatory challenges for new neuropathic pain therapeutics: Regulatory issues related to neuropathic pain product approvals; Differences between the USA and the EU regulatory perspectives; Innovative solutions utilised for recent approvals of Qutenza® in the EU and USA; Jeffrey Tobias, Chief Medical Officer, NeurogesX.
9.50 The use of quantitative human pain biomarkers in early drug development: Advanced mechanism-based human pain biomarkers; Human proof-of-concept studies in analgesic drug development; Pain mechanism based target validation; Lars Arendt-Nielsen, Director, Centre for Sensory-Motor Interaction, Aalborg University.
10.30 Morning coffee
11.00 Translational neurophysiological biomarkers of peripheral nerve function: Ion channels in peripheral nerves as a target for novel analgesic drugs and prevention of neuropathies; Nerve excitability testing provides a novel translational tool to examine non-invasively the function of different ion channel classes, including voltage-gated sodium channels and potassium channels; Drugs affect these excitability parameters differentially and allow direct assessment of target engagement; Martin Koltzenburg, Chair of Clinical Neurophysiology and Deputy Director, Centre for Neuromuscular Disease .
11.40 Discovery of TRPV1 antagonists for pain management: Issues and opportunities: Discovery of Abbott TRPV1 antagonist clinical candidate; Chemistry and preclinical pharmacology; Temperature effects of TRPV3 antagonists; Arthur Gomtsyan, Associate Research Fellow, Neuroscience and Pain Research, Abbott Laboratories.
12.20 Networking lunch
1.50 Predictive validity of animal models for analgesia - what's ahead?: Where are we with current models?; Future choices - Black-box or mechanistic modelling?; Emerging approaches; Odd-Geir Berge, Senior Principal Scientist, AstraZeneca.
2.30 Pain modulation and transmission at cannabinoid receptors: The cannabinoid receptors and pain; Agonists; Endocannabinoids; Recent developments; Future prospects; Aldemar Degroot, Associate Scientific Director, Exploratory Development Department, Astellas.
3.10 Afternoon tea
3.40 Does chromatin or epigenetic modification offer an alternative approach to the treatment of chronic, clinical pain states?: What is epigenetics?; Role of environment and stress; Evidence in pain and inflammation; Potential pitfalls; Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford.
4.20 Regulation of endogenous analgesia by the endocannabinoid system: sites and mechanisms of action: Role of the endocannabinoid system in stress-induced analgesia; Activity in supraspinal components of the descending inhibitory pain pathway; Neurochemical and molecular mechanisms; David Finn, Co-Director, Centre for Pain Research, National University of Ireland, Galway.
5.00 Chairman's closing remarks and close of day one
DAY 2
8.30 Re-registration and coffee
9.00 Chairman's opening remarks: Tim Young, Associate Research Fellow, Pfizer.
9.10 Targeting the endocannabinoid system for pain: The challenges of agonist development; Modulation of endocannabinoid tone; Future perspectives; Tim Young, Associate Research Fellow, Pfizer.
9.50 Options and pitfalls in early drug development: Experimental pain models in healthy volunteers; Phenotyping of patients with chronic pain using quantitative sensory testing; Healthy volunteer models and patient studies: potential for fMRI; Wia Timmerman, Project Leader, Pain/fMRI Research Initiative, TI Pharma.
10.30 Morning coffee
11.00 Challenges in preclinical pain research: Why work on pain research; Current animal models; The way forward; Isabel Gonzalez, Head of Biology, Proximagen Neuroscience.
11.40 Preclinical ion channel targets for next generation analgesics: Progress with isoform-selective voltage-gated sodium channel modulators; The ups and downs of TRP channels; Emerging targets; Steve England, Associate Research Fellow, Pfizer.
12.20 Networking lunch
1.50 Advances in the development of TRPA1 ligands - pharmacology and future directions: Introduction to the TRP super-family; Preclinical rationale for TRPA1; Pharmacology and insights; Efficacy in vivo; Future directions; Adrian Mogg, Research Scientist - Pain-Migraine DHT, Eli Lilly.
2.30 The use of Laser Doppler Flowmetry (LDF) to measure cutaneous blood flow in rats: a potential translational biomarker for clinical pain studies: What measurement of cutaneous blood flow can tell us about pain mechanisms: target engagement vs. surrogate end points; Optimisation and validation of a preclinical model of electrically evoked changes in blood flow using Laser Doppler Flowmetry; Advantages of this technique from an ethical perspective: the 3Rs; Sharon Bingham, In Vivo Pharmacology & Translational Science, GlaxoSmithKline.
3.10 Afternoon tea
3.40 Prostanoid EP4 receptor antagonists as novel pain therapeutics: Pivotal role of EP4 receptor in both pain and inflammation; Latest evidence from pre-clinical and experimental medicine models; EP4 receptor antagonists offer potential to be effective and better tolerated analgesics; Karen Maubach, Group Manager of Project Management, BTG.
4.20 Pharmacological characterisation of a new sigma-1 receptor antagonist for the treatment of neuropathic pain: Sigma-1 receptors play a key role in modulating activity-induced sensitisation in nociceptive pathways and are thus a new potential target of action for drugs designed to alleviate neuropathic pain; A new and selective sigma-1 receptor antagonist (S1RA) has been developed by Esteve that inhibits neuropathic pain behaviours in rodents; Safety and efficacy data support S1RA as a new therapeutic agent for the treatment of neuropathic pain; Human clinical trials are ongoing; José Miguel Vela, Basic Research & Drug Discovery, Esteve.
5.00 Chairman's closing remarks and close of conference

Conference Documentation: Pain Therapeutics (2010)

Share this report

Other tasks

Research Assistance

Related Markets

Prescription Drugs Reports

Free Alert Me service